DNA vaccination controls Her-2+ tumors that are refractory to targeted therapies.
about
Evolution of animal models in cancer vaccine developmentInterleukin-15 and its receptor augment dendritic cell vaccination against the neu oncogene through the induction of antibodies partially independent of CD4 help.A degenerate HLA-DR epitope pool of HER-2/neu reveals a novel in vivo immunodominant epitope, HER-2/neu88-102.Generation and characterization of peptide mimotopes specific for anti ErbB-2 monoclonal antibodies.The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunityCryotherapy with concurrent CpG oligonucleotide treatment controls local tumor recurrence and modulates HER2/neu immunity.Immunotherapeutic intervention with oncolytic adenovirus in mouse mammary tumors.Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination.Induction of proapoptotic antibodies to triple-negative breast cancer by vaccination with TRAIL death receptor DR5 DNA.Effective anti-neu-initiated antitumor responses require the complex role of CD4+ T cells.Targeting of antigens to B lymphocytes via CD19 as a means for tumor vaccine development.Her-2 DNA versus cell vaccine: immunogenicity and anti-tumor activity.Combining human and rat sequences in her-2 DNA vaccines blunts immune tolerance and drives antitumor immunity.Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice.CCL19 (ELC) improves TH1-polarized immune responses and protective immunity in a murine Her2/neu DNA vaccination model.Adjuvant effect of HER-2/neu-specific adenoviral vector stimulating CD8⁺ T and natural killer cell responses on anti-HER-2/neu antibody therapy for well-established breast tumors in HER-2/neu transgenic mice.
P2860
Q28080739-447FCA86-3ACE-4D3B-B7DF-B9435831F5A8Q33638464-9B77CE1E-4D65-4AA1-829D-C2C5BC3450E9Q33638509-D3C246D2-0D45-499E-8AEE-0A6080098CE3Q33907971-777648DE-6EFA-4745-ADC8-E62B6C33DEA6Q34073138-A0A3A376-1F25-4A68-8FCF-0468C128C08CQ34288183-35DCDCA0-7E5A-4156-B4BA-DDDB8EC8CC71Q35201826-781E35C7-B2CC-45A8-97C2-9067C248E237Q35815995-66438317-546B-47B5-A57C-A00DA81004D4Q36070101-F4D6956E-5140-41A9-878B-1DCE44812C85Q36698273-8A958C5B-4445-4B22-BEA3-8F03AC3BA617Q36864003-77EDB920-18D9-455F-9255-234937AFC167Q37307584-ECAF2230-2979-4E68-B9D7-735136ED63ADQ37626805-60AE57CB-70C4-4FC3-BC09-210BDBF51F6FQ47946808-7581E361-0E68-489D-A064-E85BEB50A458Q52890329-6CC68316-1DF2-43B4-81B8-F1A92EB02DA0Q53248364-7B87D23F-E6B9-4607-A8EE-985D6EE96174
P2860
DNA vaccination controls Her-2+ tumors that are refractory to targeted therapies.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
DNA vaccination controls Her-2+ tumors that are refractory to targeted therapies.
@en
type
label
DNA vaccination controls Her-2+ tumors that are refractory to targeted therapies.
@en
prefLabel
DNA vaccination controls Her-2+ tumors that are refractory to targeted therapies.
@en
P2093
P2860
P1433
P1476
DNA vaccination controls Her-2+ tumors that are refractory to targeted therapies.
@en
P2093
Henry H Heng
Jennifer B Jacob
Jessica B Back
Marie P Piechocki
Paula J Whittington
Richard F Jones
Wei-Zen Wei
P2860
P304
P356
10.1158/0008-5472.CAN-08-1489
P407
P577
2008-09-01T00:00:00Z